Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.

Scientific reports - 23 Mar 2017

Nomizo Takashi, Ozasa Hiroaki, Tsuji Takahiro, Funazo Tomoko, Yasuda Yuto, Yoshida Hironori, Yagi Yoshitaka, Sakamori Yuichi, Nagai Hiroki, Hirai Toyohiro, Kim Young Hak

Abstract excerpt

This study was intended to determine the efficacy of nivolumab, we evaluated treatment response with respect to PD-1/PD-L1 SNPs among patients with NSCLC. A total of 50 patients with NSCLC were treated with nivolumab and were also evaluated for PD-1/PD-L1 single nucleotide polymorphisms (SNPs) from plasma DNA. We investigated the association among PD-1/PD-L1 SNPs, objective response rate (ORR) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Carcinoma, Non-Small-Cell Lung

Share to Kaplan-Meier Estimate

Share to Neoplasm Staging

Share to Nivolumab

Share to Programmed Cell Death 1 Receptor

Source

Open in PubMed Open full text

Identifiers

PMID: 28332580
DOI: 10.1038/srep45124
PMCID: PMC5362817

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.PMID 28332580Read ↗

PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.Semantic proximity Read ↗

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLCSemantic proximity Read ↗

Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancer.Semantic proximity Read ↗

Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab.Semantic proximity Read ↗

PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors.Semantic proximity Read ↗

Polymorphisms of the PD-L1 gene 3'-untranslated region are associated with the expression of PD-L1 in non-small cell lung cancer.Semantic proximity Read ↗

Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients.Semantic proximity Read ↗

Prognostic implication of PD-L1 polymorphisms in non-small cell lung cancer treated with radiotherapy.Semantic proximity Read ↗

Association Between Genetic Variants and the Risk of Nivolumab-Induced Immune-Related Adverse EventsSemantic proximity Read ↗

Impact of copy number variant and single nucleotide polymorphism of the programmed death‑ligand 1 gene, programmed death‑ligand 1 protein expression and therapy regimens on overall survival in a large group of Caucasian patients with non‑small cell lung carcinomaSemantic proximity Read ↗

PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy.Semantic proximity Read ↗

A multicenter prospective study of single nucleotide polymorphisms in the PDCD1 (programmed cell death 1) gene in patients with metastatic lung adenocarcinoma treated with pembrolizumab.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.